Protocol Title: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer

Sponsor: Seagen

Protocol Number: SGN-TUA-029

Key Criteria

·         First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer
 
·         Have RAS WT disease as determined by local or central testing
 
·         CANNOT have previously received any systemic anticancer therapy for CRC in the metastatic setting or have participated in any interventional clinical trial for CRC in the metastatic setting. Subjects may have received prior chemotherapy for CRC in the adjuvant setting provided that it was completed >6 months prior to enrollment.
 
·         CANNOT have previously been treated with anti-HER2 therapy

Talking Points

Scroll to Top